

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/735,973
Filing Date	December 15, 2003
First Name Inventor	Certa et al.
Attorney Docket Number	21507 US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	A				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ³
		Office ²	Number ²	Kind Code ² (if known)			
IC	B1	WO	02/074992		Decode Genetics EHF	09/26/2002	
IC	B2	WO	00/09504		Pfizer Products Inc.	02/24/2000	
IC	B3	WO	01/35979		ICOS Corporation	05/25/2001	
IC	B4	WO	01/68600		Inflazyme Pharm. Ltd.	09/20/2001	
IC	B5	WO	98/45268		Pfizer Products Inc.	10/15/1998	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					T ³
IC	C1	Beard, M. B. et al., Cellular Signalling Vol. 14 (2002) pgs. 453-465					
	C2	Beavo et al., Molecular Pharmacology Vol. 46, pgs. 399-405 (1994)					
	C3	Perry & Higgs, Curr. Opinion Chem. Biol. Vol. 2 pgs. 472-481 (1998)					
	C4	Houslay & Milligan, Trends in Biochem. Sci. Vol. 22 pgs. 217-224 (1997)					
	C5	Beavo & Reifsnnyder, Trends Pharmacol. Sci. Vol. 11, pgs. 150-155 (1990)					
	C6	Bolger et al., Mol. Cell. Biol. Vol. 13 pgs. 6558-6571 (1993)					
	C7	Houslay, Sullivan & Bolger, Adv. Pharmacol. Vol. 44, pgs. 225-245 (1998)					
	C8	McPhee et al. Biochem. J. Vol. 310, pgs. 965-974 (1995)					
	C9	Hughes et al. Drug Discov. Today, Vol. 2, pgs. 89-101 (1997)					
	C10	Torphy, Am. J. Respir. Crit. Care Med. Vol. 157, pgs. 351-370 (1998)					
	C11	Teixeira et al. Trends Pharm. Sci. pgs. 164-171 (1997)					
	C12	Entman & Smith, Cardiovasc. Res. Vol. 28, pgs. 1301-1311 (1994)					
	C13	Bowie, Science Vol. 247 (1990) pgs. 1306-1310					
	C14	Fritz & Anderson, Methods in Enzymology (2000) Vol. 327, pgs. 3-16					
	C15	Hopp, T. P. (1988) Biotechnology Vol. 6, pgs. 1204-1210					
	C16	Sisk et al. (1994) J. Virol. Vol. 68, pgs. 766-775					
IC	C17	Owens, et al. Biochem. J. (1997) 326; 53-60					
Examiner Signature	Date Considered /Iqbal Chowdhury/ (09/04/2006)						

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language translation or abstract is attached

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

JUN 18 2006

Complete if Known

Application Number	10/735,973
Filing Date	December 15, 2003
First Name Inventor	Certa, et al.
Group Art Unit	1652
Examiner Name	I. Chowdh
Attorney Docket Number	21507 US

Sheet	1	of	4
-------	---	----	---

PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.*	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T*
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
IC	B6	WO 02/22661		A2	BEAVO, JOSEPH A., et al	03-21-2002	
Examiner Signature		Date Considered			/Iqbal Chowdhury/ (09/04/2006)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.



Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/735,973
(Use several sheets if necessary)		Filing Date	December 15, 2003
Sheet 1 of 1		First Name Inventor	Certa et al.
		Attorney Docket Number	21507 US

U.S. PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	A				

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ³
		Office ⁴	Number ⁴	Kind Code ² (if known)			
IC	B1	WO	02/074992	✓	Decode Genetics EHF	09/26/2002	
IC	B2	WO	00/09504	✓	Pfizer Products Inc.	02/24/2000	
IC	B3	WO	01/35979	✓	ICOS Corporation	05/25/2001	
IC	B4	WO	01/68600	✓	Inflazyme Pharm. Ltd.	09/20/2001	
IC	B5	WO	98/45268	✓	Pfizer Products Inc.	10/15/1998	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ³
IC	C1	Beard, M. B. et al., Cellular Signalling Vol. 14 (2002) pgs. 453-465	
	C2	Beavo et al., Molecular Pharmacology Vol. 46, pgs. 399-405 (1994)	
	C3	Perry & Higgs, Curr. Opinion Chem. Biol. Vol. 2 pgs. 472-481 (1998)	
	C4	Houslay & Milligan, Trends in Biochem. Sci. Vol. 22 pgs. 217-224 (1997)	
	C5	Beavo & Reifsnnyder, Trends Pharmacol. Sci. Vol. 11, pgs. 150-155 (1990)	
	C6	Bolger et al., Mol. Cell. Biol. Vol. 13 pgs. 6558-6571 (1993)	
	C7	Houslay, Sullivan & Bolger, Adv. Pharmacol. Vol. 44, pgs. 225-245 (1998)	✓
	C8	McPhee et al. Biochem. J. Vol. 310, pgs. 965-974 (1995)	
	C9	Hughes et al. Drug Discov. Today, Vol. 2, pgs. 89-101 (1997)	
	C10	Torphy, Am. J. Respir. Crit. Care Med. Vol. 157, pgs. 351-370 (1998)	
	C11	Teixeira et al. Trends Pharm. Sci. pgs. 164-171 (1997)	
	C12	Entman & Smith, Cardiovasc. Res. Vol. 28, pgs. 1301-1311 (1994)	
	C13	Bowie, Science Vol. 247 (1990) pgs. 1306-1310	
	C14	Fritz & Anderson, Methods in Enzymology (2000) Vol. 327, pgs. 3-16	
	C15	Hopp, T. P. (1988) Biotechnology Vol. 6, pgs. 1204-1210	
	C16	Sisk et al. (1994) J. Virol. Vol. 68, pgs. 766-775	
IC	C17	Owens, et al. Biochem. J. (1997) 326; 53-60	
Examiner Signature		Date Considered /Iqbal Chowdhury/ (09/04/2006)	

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
²Unique citation designation number. See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.